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Introduction: Genetic variants for breast cancer risk identified in genome-wide association studies (GWAS) in
Western populations require further testing in Asian populations. A risk assessment model incorporating both validated
genetic variants and established risk factors may improve its performance in risk prediction of Asian women.
Methods: A nested case-control study of female breast cancer (411 cases and 1,212 controls) within the Singapore
Chinese Health Study was conducted to investigate the effects of 51 genetic variants identified in previous GWAS on
breast cancer risk. The independent effect of these genetic variants was assessed by creating a summed genetic risk
score (GRS) after adjustment for body mass index and the Gail model risk factors for breast cancer.
Results: The GRS was an independent predictor of breast cancer risk in Chinese women. The multivariate-adjusted
odds ratios (95% confidence intervals) of breast cancer for the second, third, and fourth quartiles of the GRS
were 1.26 (0.90 to 1.76), 1.47 (1.06 to 2.04) and 1.75 (1.27 to 2.41) respectively (P for trend <0.001). In addition to
established risk factors, the GRS improved the classification of 6.2% of women for their absolute risk of breast
cancer in the next five years.
Conclusions: Genetic variants on top of conventional risk factors can improve the risk prediction of breast
cancer in Chinese women.Introduction
Breast cancer is a heterogeneous disease that is associated
with genetic and environmental factors. Prior to genetic
studies, investigations have mainly revolved around the
presence of a family history, hormonal and reproductive-
related risk factors [1-3] with the effects of other lifestyle
factors being queried recently. To date, the risk of disease
has been shown to increase with a woman’s age, age at
menopause, age at first live birth, previous occurrence of
atypical hyperplasia and family history [4]. The inherited
predisposition to this malignancy has also been thoroughly
studied to reveal two major susceptibility genes, BRCA1* Correspondence: mikael_hartman@nuhs.edu.sg
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reproduction in any medium, provided the orand BRCA2 [5,6], as well as other gene mutations of lower
penetrance [7-12]. However, these account for less than 5%
of breast cancer cases, suggesting a more widespread rele-
vance of common genetic variants in the population when
considered cumulatively [13-17]. In addition, migrant and
twin studies have hinted of an environmental component
that can possibly overwrite the genetic influences on breast
cancer, suggesting a multi-factorial nature of breast cancer
risk or gene-environment interactions [18,19].
In an attempt to increase the clinical utility of these
findings [20], statistical models have been designed and
validated to aid in personalized risk assessment. Notably,
the Gail model is the most widely used for breast cancer
risk prediction. However, the model does not consider
genetic factors directly [1] and has limited discriminatory
power [21]. On the contrary, other studies in general have
until recently ignored hormonal and reproductive charac-
teristics of individual women [22,23]. Unfortunately, most. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[24-27] and may be inapplicable to Chinese populations.
Despite having a much lower breast cancer incidence in
Asia than in Europe [28], a rapidly increasing trend toward
rates in the West is a cause for concern [29]. Singapore
women are reported to have one of the highest rates of
breast cancer incidence in the region with an annual in-
crease of more than 3% [30]. As the linkage disequilib-
rium patterns differ among ethnic groups [31], findings
from genome-wide association studies (GWAS) done on
Caucasian populations [7,32-36] are potentially less relevant
to Asian women [31,37-39]. In this nested case-control
study, we incorporated a set of established GWAS risk
alleles into a model with well-known lifestyle factors
and evaluated its impact on predicting breast cancer
risk in a Singapore Chinese cohort.
Methods
Study subjects
The subjects included in this study are women enrolled in
the Singapore Chinese Health Study (SCHS), a population-
based cohort study which has been described in detail pre-
viously [40]. Briefly, the cohort comprises 63,257 Chinese
men and women between the ages of 45 to 74 who were
recruited from 1993 to 1998. Participants were Singapore
citizens or permanent residents who lived in government-
built housing estates, and belonged to either of two major
dialect groups: Hokkien or Cantonese. All participants were
interviewed at baseline in their homes where they provided
information on demographics, diet, level of physical activity,
occupational exposure, smoking, and medical history.
The women were also asked about their menstrual and
reproductive history.
Between April 1994 and December 1999, blood and
single-void urine specimens were collected from a random
3% sample of study enrollees. Details of the biospecimen
collection, processing and storage procedures have been
described previously [41]. Between January 2000 and April
2005, we extended our biospecimen collection to all sur-
viving cohort members and collected biospecimens from
32,575 participants, representing a consent rate of about
60% of surviving cohort participants at that time.
Informed consent was obtained from all participants
at baseline interview, as well as at time of biospecimen
collection. The Institutional Review Board at the National
University of Singapore has approved this study.
Case ascertainment
Incident breast cancer cases were identified through the
population-based cancer registry in Singapore. As of
28 June 2010, 941 had developed breast cancer in this
cohort and among them, 414 donated blood previously
and were included in this study. Compared with breast
cancer patients who did not donate a blood sample,those who donated were younger at diagnosis (54.9 versus
56.0 years). Patients who did not donate blood samples
were less educated (39.1% had no formal education) than
those who did (25.1% had no formal education). There
was also a higher proportion of family history of breast
cancer among those who donated blood (n = 11, 2.66%)
compared to those who did not donate (n = 4, 0.76%).
Control selection
For each of the 414 breast cancer cases, up to three con-
trol subjects were randomly selected among all female
cohort participants who had donated blood samples, and
who were alive and free of breast cancer history at the
time of cancer diagnosis of their index case. The chosen
controls were matched to the index case on age at study
enrollment (±3 years), dialect group (Hokkien, Cantonese),
menopausal status at sample collection, dates of study en-
rollment (±2 years) and of blood collection (±6 months).
For the 414 cases, there were six cases where only two
eligible controls were found for each of them, and 408 cases
where three controls were found for each of them.
SNP selection, genotyping and quality control
We reviewed all published GWAS results related to breast
cancer [42]. Single nucleotide polymorphisms (SNPs) from
various studies [43-45], including more than 40 novel SNPs
that were very recently identified from the Breast Cancer
Association Consortium (BCAC) [46] and subsequently
evaluated in a collaborative study on East Asian women
[39], were evaluated for their application in breast cancer
risk assessment. Due to differences in haplotype structure
between Caucasian and Chinese populations, among SNPs
in the same loci and having linkage disequilibrium (LD, r2)
of more than 0.8 in HapMap Han Chinese in Beijing (CHB)
population [47], the SNP with the greatest statistically sig-
nificant association with breast cancer was genotyped, to
ensure that all SNPs analyzed for risk prediction were inde-
pendent of each other. SNPs with minor allele frequencies
(MAF) less than 5% according to the Singapore Genome
Variation Project (SGVP) [48] were also excluded.
Genotyping was done using the Sequenom iPLEX
Gold MassARRAY system in 96-well plates (Sequenom,
San Diego, CA, USA). MassARRAY Assay Design software
was used to design amplification and extension primers
(Sequenom). Multiplex PCR amplification was performed
using Qiagen HotStart Taq DNA polymerase with 10 ng of
genomic DNA (Qiagen, Germantown, MD, USA). Finally,
primer extension reactions were carried out according to
manufacturer’s guidelines. The investigators were blinded
to the case/control status of the samples.
Of the initial 69 SNPs, seven SNPs (rs3803662,
rs4808801, rs8100241, rs11199914, rs11814448, rs10069690
and rs1292011) could not be analyzed further as they pro-
duced poor, indistinguishable clusters, which could result in
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SNPs was 98%, however the minor allele frequencies of
rs11571833, rs132390, rs1045485, rs614367, rs999737 and
rs8170 fell below the 1% threshold and were removed from
analysis due to low power to detect any association with
breast cancer. Deviation from Hardy-Weinberg equilibrium
(P <0.0007) in controls was exhibited in the genotype distri-
bution of rs7716600 and these SNPs were also discarded.
Among the samples, three cases and fifteen controls did not
meet the minimum call rate of 90%. The entire matched set
was removed from analyses in the former. Therefore,
55 GWAS SNPs and 1,623 subjects (411 cases and
1,212 controls) were used for further data analyses.
Data analysis
The SCHS questionnaire contained demographic data,
reproductive risk factors, as well as information on diet
and lifestyle. Risk factors to be included in the prediction
model were selected according to results reported from
other studies done on the SCHS cohort and factors used
in the original Gail model [1]. Variables in the model
were: level of education (no formal schooling, primary
school, or secondary school or above), age at first live
birth (<20, 20 to 24, 25 to 29 or nulliparous, ≥30 years),
age at menarche (≥14, 12 to 13, <12 years), history of
past breast biopsy (yes, no), family history (yes, no), body
mass index (BMI) (<20, 20 to 23.9, 24 to 27.9, ≥28 kg/m2)
and genetic risk score (GRS) in quartiles based on the
controls. BMI was calculated as the weight divided by
the squared height (kg/m2). Family history was limited
to first-degree relatives only. The history of past breast
biopsy (yes/no) was known for 218 (13.2%) women in the
current nested case-control sample. For the remaining
women with unknown history of breast biopsy, we imputed
the value of history of breast biopsy variable by generating
five values and picking the most frequent one, with BMI,
estrogen and family history as predictors.
The association between breast cancer and demographic,
reproductive, and other baseline characteristics was investi-
gated using the Student’s t test and Mantel-Haenszel
chi-squared test (linear by linear association) for continu-
ous and categorical variables respectively. Established risk
factors namely, parity, age at first live birth, age at menar-
che, age at menopause, BMI, family history, history of past
breast biopsy and estrogen use were examined for their
independent associations with breast cancer risk. A GRS
was derived for each individual to represent the cumulative
effect of the genetic variants on a woman’s risk of breast
cancer. The Cochran’s Q test [49], which is the weighted
sum of the squared difference between individual and
pooled effects across studies, was used to test for het-
erogeneity among the current and published studies.
The P values were obtained by comparing the statistic with
a chi-square distribution with k-1 degrees of freedom,where k is the number of studies. SNPs were included
in the computation of GRS only if heterogeneity was
not statistically significant. If not, they were removed
on the basis of inconsistency among studies (rs11780156,
rs6504950, rs6001930, and rs2981579). To account for
multiple hypothesis testing, a false discovery rate (FDR)
correction according to the Benjamini-Hochberg proced-
ure [50] was applied. A total of 51 SNPs was included in
the computation of GRS. All SNP selection criteria had
been decided a priori.
A fixed-effects meta-analysis of published GWAS and
our study’s findings was performed in order to obtain
reliable estimates for each SNP’s effect size in the form
of a pooled odds ratio (pOR) derived from published and
local studies. We weighted the effect size estimates of each
study using the inverse of the corresponding standard er-
rors of the respective studies. The GRS for an individual
woman is equivalent to the sum of (log pOR of SNP) ×
(number of risk alleles that the individual carries for SNP)
across all 51 SNPs. The GRS was normalized by dividing it
by the average effect size of all SNPs in the population, as
outlined previously [51]. Box plots were used to investigate
the correlation between GRS and various breast cancer
risk factors: age at first live birth, age at menarche,
family history, past breast biopsy, BMI and education.
Conditional logistic regression was used to calculate
the crude and adjusted ORs with a 95% confidence interval
for each risk factor. The P value for trend across categories
was reported.
Variables in the Gail model and BMI were used to
construct the conditional logistic regression model. The
models with and without a GRS were compared in terms
of their ability to accurately assess a woman’s five-year
absolute risk. The probability that an individual i would
be free of breast cancer beyond a certain time point, Pi
(t), was calculated as 1-(St)
Ci, where St is the proportion
of people who were not diagnosed with breast cancer
(survived) up to time point t. We estimated St using a
Kaplan-Meier survival curve, based on data from the SCHS
cohort - the cohort that this nested case-control study is
from. Since a five-year risk is required in this study, t = 5
years. The individual-level coefficient, Ci is determined by
the formula exp[∑βj(xij - μj)], where βj is the log odds ratio
(OR) of the risk conferred by a variable j, and xij refers to
the value of variable j for individual. The average for the
variable in the population, μj, was approximated using the
average among controls. The benefit of adding genetic
markers into the predictive model was assessed using a net
reclassification improvement (NRI) index [52] that com-
pares the risk classifications under models with and without
GRS, to adjust the NRI index for overfitting, the index was
further corrected using a bootstrap procedure [53].
As there is general expectation of a more reliable risk
prediction model as additional risk variants become
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the model with six, nine, eleven, sixteen and fifty-one
(this study) SNPs. These SNPs were chosen in an order
in which their association with breast cancer risk was
established through time [26,27,57-60].
Conditional logistic regression for the association be-
tween SNPs and breast cancer risk, NRI calculation
and histogram plots were performed using R version
2.13.0. All other statistical analyses were performed using
IBM SPSS version 21.0 (IBM Corp., Armonk, NY, USA).
Statistical tests were two-sided and P <0.05 was consid-
ered statistically significant. In the test for heterogeneity,
P <0.007 was used after accounting for multiple testing
through Bonferroni correction.
Results
In total, 411 cases and 1,212 controls were used in the
analyses. The distribution of subjects by background
characteristics is shown in Table 1. As the cases and
controls were matched on age and menopausal status,
they were comparable in these aspects. Cases tend to be
more well-educated (P = 0.003), older at first live birth
(P = 0.022), report a younger age at menarche (P = 0.033),
tend to be current estrogen users (P = 0.042) and fall under
a higher GRS quartile (P < 0.001) compared to controls.
They also have higher BMI (P = 0.066) and a positive
family history of breast cancer (P = 0.063). The remaining
factors comprising sleep and dietary patterns did not differ
significantly between the two groups. Figure 1 displays no
statistically significant correlation between GRS and the
various breast cancer risk factors.
The ORs of the 51 SNPs from the current study and
their pooled estimates with previous GWAS studies are
displayed in Table 2. The SNPs that tag the ESR1 loci -
rs2046210 and rs3757318, presented ORs that were statisti-
cally significant at the 5% level. Associations with FOXQ1
(P = 0.088) and TOX3 (P = 0.098) displayed marginal
significance. Apart from two tag SNPs for ESR1, an-
other six SNPs (rs11552449, rs13387042, rs10759243,
rs3903072, rs12422552, rs2236007) were also significantly
associated with breast cancer in our study. Table S1 in
Additional file 1 shows the corresponding pooled esti-
mates when only published studies were used.
The associations between breast cancer risk, established
risk factors and GRS were evaluated. Compared to the
lowest quartile, women in the highest GRS quartile
were close to 80% (OR = 1.75, 95% confidence interval
(CI) = 1.27 to 2.41) more likely to have breast cancer
(Table 3). The magnitude of the association with GRS
and the dose-response relationship remained almost
unchanged even after adjusting for the established risk
factors and education. Age at first live birth and age at
menarche presented statistically significant trends with
breast cancer risk, but were no longer significant afteradjustment. On the contrary, the association of BMI
with risk became significant after other factors were
considered. After accounting for GRS and the above-
mentioned risk factors, neither a positive family history
nor a previous breast biopsy was significantly associated
with breast cancer risk.
A NRI index was used to assess the improvement in
risk classification that would result from adding GRS to
a model comprising established risk factors only. Table 4
shows the distribution of women across the various
five-year absolute risk categories from <1.0% to ≥2.5%.
Approximately 1,400 women reported five-year cumula-
tive risks of less than 1.5%, while only 5.4% of cases and
2.0% of controls were assigned into high-risk groups of 2%
or more. Among the 44 cases who were categorized as
having a five-year absolute risk of 1.5% to <2.0% under the
model without GRS, 12 of them were shifted to higher risk
groups while 13 were moved to the lower risk category of
1.0% to <1.5% when GRS was added to the model. Simi-
larly, for about 46.1% of the controls who were initially
estimated to have 1.5% to <2.0% risk based on established
risk factors only, the new model with GRS indicated a
lower risk of 1.0% to <1.5%, while shifting 12 individuals
to the 2.0% to <2.5% risk stratum. The reclassification im-
provement among cases was 11.2% (P <0.001), while that
for controls was 2.2% (P = 0.04), though the latter was not
statistically significant. This led to an NRI of 13.4% (P =
0.006), which decreased to 6.2% after correcting for opti-
mism using a bootstrap method. This meant, that overall,
6% of women were reclassified into more appropriate risk
groups when a genetic component was considered.
Figure 2 demonstrates the change in model discrimin-
atory power as GRS that represented the cumulative effect
of six, nine, eleven, sixteen and fifty-one (this study) SNPs
were used in predicting the five-year absolute risk. A mar-
ginal improvement in model performance was noted.
Discussion
We have evaluated a total of 51 SNPs and constructed a
GRS to reflect their cumulative effect on breast cancer
risk. The genetic score was independently associated
with breast cancer risk after adjusting for education and
other established risk factors. These common genetic
markers, when considered in aggregate, together with re-
productive factors and BMI, can improve the risk strati-
fication for close to 10% of Singapore Chinese women.
Similar to past SCHS studies [61,62], cases tend to be
more highly educated compared to the controls, hence
the adjustment for education in the conditional logistic
regression model. However, BMI and family history did
not differ significantly between the two groups although
the direction of the associations was in agreement with
prior knowledge. Failure to reach statistical significance is
very likely due to the sample size, hence limiting our study’s
Table 1 Distribution of demographic and established risk
factors for breast cancer in cancer patients (cases) and
control subjects, The Singapore Chinese Health Study,
1993 to 1998
Cases
(n = 411)
Controls
(n = 1,212)
P*
Demographic factors
Mean age, years (SD) 54.9 (7.6) 54.9 (7.5) 0.964
Education level, n (%) 0.003
None 104 (25.3) 399 (32.9)
Primary 186 (45.3) 518 (42.7)
Secondary or higher 121 (29.4) 295 (24.3)
Reproductive risk factors
Number of live births, n (%) <0.001
Nulliparous 56 (13.6) 85 (7.0)
1-2 146 (35.5) 369 (30.4)
3-4 131 (31.9) 483 (39.9)
5 or more 78 (19.0) 275 (22.7)
Mean age at first live birth, years (SD) 25.6 (4.9) 25.0 (4.7) 0.022
Mean age at menarche, years (SD) 14.1 (1.7) 14.3 (1.8) 0.033
Mean age at menopause, years (SD) 49.7 (4.4) 49.2 (4.3) 0.141
Estrogen use, n (%) 0.042
Non-user 372 (90.5) 1,131 (93.3)
Ex-user 8 (1.9) 22 (1.8)
Current user 31 (7.5) 59 (4.9)
Other risk factors
Family history of breast cancer, n (%) 0.063
No 400 (97.3) 1,196 (98.7)
Yes 11 (2.7) 16 (1.3)
History of past biopsy, n (%) 0.252
No 401 (97.6) 1,193 (98.4)
Yes 10 (2.4) 19 (1.6)
Mean body mass index, kg/m2 (SD) 23.5 (3.4) 23.2 (3.2) 0.066
Marine n-3 omega fatty acids, g (SD) 0.90 (0.4) 0.90 (0.5) 0.299
Vegetable-fruit-soy intake, n (%) 0.969
0 79 (19.2) 241 (19.9)
1 99 (24.1) 307 (25.3)
2 130 (31.6) 332 (27.4)
3 103 (25.1) 332 (27.4)
Green tea intake in tertiles, n (%) 0.418
None 234 (56.9) 713 (58.8)
First 77 (18.7) 219 (18.1)
Second 43 (10.5) 134 (11.1)
Third 57 (13.9) 146 (12.0)
Mean isoflavanoids, mg (SD) 19.4 (20.4) 19.8 (17.3) 0.700
Sleep duration, hours per day (SD) 7.0 (1.1) 7.0 (1.1) 0.685
Genetic risk score in quartiles, n (%)
Table 1 Distribution of demographic and established risk
factors for breast cancer in cancer patients (cases) and
control subjects, The Singapore Chinese Health Study,
1993 to 1998 (Continued)
First (32.4 - 43.6) 80 (19.5) 326 (26.9) <0.001
Second (43.6 - 47.1) 96 (23.4) 310 (25.6)
Third (47.1 - 50.6) 109 (26.5) 296 (24.4)
Fourth (50.6 - 65.8) 126 (30.7) 280 (23.1)
*Two-sided P values were derived from chi-squared test for categorical
variables and t test for continuous variables; the Mantel-Haenszel chi-squared
test for trend with one degree of freedom for categorical variables with more
than two levels. SD, standard deviation.
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ily history (OR = 1.78) after accounting for GRS was noted
too. This could be due to the fact that risk variants, which
are directly or indirectly incorporated into the GRS are also
traits that tend to be inherited together.
To our knowledge, we have investigated the largest num-
ber of SNPs for use in risk assessment in an Asian popula-
tion. Studies by Dai et al., Sueta et al., and Zheng et al.
have reported the discriminatory power of using five,
seven and eight SNPs respectively [37,54,55]. All groups
demonstrated the clinical utility that can potentially be
achieved with the incorporation of common genetic vari-
ants to a model containing established risk factors. Lo-
cally, a group has reported the potential effect of
combining eight SNPs with clinicopathological factors in
risk prediction for a Singapore Chinese population [56].
Likewise, we have shown that common genetic markers,
when considered in aggregate, together with reproductive
factors and BMI, can improve the risk stratification for
close to 10% of Singapore Chinese women. However, the
majority of the cases (79.6%) presented low five-year cu-
mulative risks of less than 1.5% after GRS was considered,
with only 5.4% being assigned five-year cumulative risks of
2% or more. This suggests that other genetic, physiological
and environmental factors not accounted for in this study,
which includes novel factors yet to be identified, still ac-
count for a large proportion of risk for breast cancer in this
population.
To gauge how much value a genetic component can
add to an individual’s risk assessment, we included the
GRS into a model consisting of Gail variables and com-
pared its performance with the model without GRS.
Many of the studies published thus far have reported the
accuracy of their models in terms of area-under-the-curve
(AUC) values [63]. However, AUC is insensitive even
when strong predictors are added to the model [64], hence
could partially account for insignificant increases in model
discrimination. It also does not provide information about
the actual risks predicted, therefore, its direct clinical rele-
vance is limited [65]. Instead, we have quantified the de-
gree of correct risk reclassification by calculating the NRI
Figure 1 Correlation of genetic risk score (GRS) with various breast cancer risk factors. No statistically significant correlation was observed
between GRS and the following breast cancer risk factors: age at first live birth, age at menarche, family history, past history of breast biopsy,
body mass index (BMI) and education.
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points, it is robust to moderate changes [66]. Bootstrap-
ping was performed to account for overfitting of our data
to the model, which could in turn lead to an overesti-
mation of model performance. Although we attempted to
incorporate all variables of the Gail model in our study,
the low uptake of screening mammography meant that we
did not have breast biopsy information for a majority
of our participants. This problem of ‘missing data’ was
overcome by imputing breast biopsy status based on BMI,
estrogen use and family history - variables that differed
between those who ever and never had a breast biopsy.SNPs that tagged the ESR1 gene, which codes for estro-
gen receptor alpha (ESRα), presented statistically significant
associations and consistent ORs in our study. This is in
concordance with findings from other groups, which
showed substantial effect sizes for SNPs in this region,
highlighting a likely association with breast cancer among
Chinese and Japanese women [67]. The study conducted
among Singaporean Chinese also reported that rs2046210
recorded the largest magnitude, similar to our current
study [56]. This is in agreement with a comparison study
by Hein et al., which found significant association of the
6q25.1 locus in both Asians and Europeans but greater
Table 2 The rare allele frequencies of 51 single nucleotide polymorphisms (SNPs) in breast cancer patients and control
subjects and their association with risk of breast cancer, The Singapore Chinese Health Study, 1993 to 1998
Chr Genes in or near region SNP Effect
allele
RAF in
controls
RAF in
cases
Per-allele
OR (95% CI)
SE P value* Pooled
OR
FDR-corrected
Phet
1 PEX14 rs616488 G 0.348 0.361 1.06 (0.89, 1.26) 0.09 0.510 0.94 0.790
1 PTPN22/BCL2L15/AP4B1/DCLRE1B/HIPK1 rs11552449 A 0.596 0.556 0.85 (0.72, 0.99) 0.08 0.040 1.06 0.068
1 FCGR1B rs11249433 G 0.029 0.026 0.85 (0.52, 1.39) 0.25 0.517 1.09 0.371
2 INHBB- rs4849887 A 0.259 0.269 1.05 (0.87, 1.25) 0.09 0.634 0.92 0.561
2 METAP1D/DLX1/DLX2 rs2016394 A 0.195 0.191 0.96 (0.79, 1.18) 0.10 0.727 0.95 0.790
2 TNP1‡ rs13387042 G 0.907 0.883 0.77 (0.60, 0.99) 0.13 0.045 0.93 0.062
2 DIRC3 rs16857609 C 0.376 0.367 1.07 (0.90, 1.27) 0.09 0.462 1.08 0.977
3 ITPR1/EGOT rs6762644 G 0.098 0.096 0.97 (0.73, 1.29) 0.14 0.841 1.07 0.790
3 SLC4A7 rs4973768 A 0.190 0.186 0.97 (0.80, 1.18) 0.10 0.757 1.11 0.473
3 TGFBR2 rs12493607 G 0.278 0.262 0.91 (0.76, 1.09) 0.09 0.290 1.06 0.619
4 TET2 rs9790517 A 0.613 0.635 1.09 (0.93, 1.29) 0.08 0.293 1.05 0.440
4 ADAM29 rs6828523 A 0.275 0.271 0.99 (0.82, 1.18) 0.09 0.879 0.90 0.729
5 5p12 (intergenic) rs4415084 C 0.441 0.434 0.96 (0.82, 1.14) 0.08 0.668 1.15 0.087
5 MRPS30 rs10941679 G 0.499 0.519 1.09 (0.93, 1.29) 0.08 0.289 1.12 0.409
5 MAP3K1‡ rs889312 C 0.589 0.577 0.96 (0.82, 1.14) 0.08 0.666 1.05 0.727
5 RAB3C rs10472076 G 0.247 0.260 1.07 (0.89, 1.28) 0.09 0.465 1.04 0.500
5 EBF1 rs1432679 G 0.631 0.642 1.05 (0.89, 1.24) 0.08 0.558 1.07 0.931
6 FOXQ1† rs11242675 A 0.597 0.633 1.15 (0.98, 1.35) 0.08 0.088 - -
6 ECHDC1/RNF146 rs2180341 G 0.181 0.198 1.09 (0.90, 1.33) 0.10 0.365 1.31 0.100
6 RANBP9 rs204247 G 0.588 0.611 1.10 (0.94, 1.29) 0.08 0.248 1.05 0.911
6 FAM46A rs17529111 G 0.218 0.206 0.92 (0.75, 1.12) 0.10 0.404 1.06 0.675
6 ESR1 rs3757318 A 0.276 0.316 1.20 (1.01, 1.42) 0.09 0.039 1.04 0.790
6 ESR1‡ rs2046210 A 0.380 0.434 1.25 (1.06, 1.46) 0.08 0.008 1.27 0.970
7 ARHGEF5 rs720475 A 0.046 0.041 0.90 (0.61, 1.33) 0.20 0.596 0.94 0.941
8 RPL17P33 rs9693444 A 0.282 0.288 1.04 (0.87, 1.24) 0.09 0.691 1.07 0.977
8 8q24 rs13281615 G 0.502 0.500 0.99 (0.84, 1.16) 0.08 0.872 1.07 0.215
8 8q24 rs1562430 C 0.181 0.184 1.03 (0.83, 1.27) 0.11 0.820 0.87 0.273
9 CDKN2A rs1011970 A 0.096 0.095 0.98 (0.75, 1.28) 0.14 0.875 1.07 0.639
9 KLF4 rs10759243 A 0.431 0.476 1.20 (1.02, 1.41) 0.08 0.027 1.06 0.790
9 KLF4 rs865686 C 0.057 0.067 1.19 (0.87, 1.64) 0.16 0.275 0.90 0.150
10 ZNF365 rs10822013 T 0.500 0.517 1.07 (0.91, 1.25) 0.08 0.409 1.08 0.387
10 ZNF365‡ rs10995190 A 0.012 0.013 1.14 (0.57, 2.30) 0.36 0.713 1.06 0.350
10 ZMIZ1 rs704010 A 0.369 0.397 1.12 (0.95, 1.33) 0.08 0.169 1.08 0.473
10 FGFR2‡ rs1219648 G 0.404 0.427 1.08 (0.92, 1.27) 0.08 0.343 1.14 0.560
10 FGFR2 rs2981582 A 0.338 0.370 1.14 (0.96, 1.34) 0.08 0.128 1.26 0.451
11 LSP1 rs3817198 G 0.095 0.108 1.14 (0.89, 1.46) 0.13 0.311 1.07 0.931
11 DKFZp761E198/OVOL1/SNX32/CFL1 rs3903072 A 0.210 0.175 0.81 (0.66, 0.99) 0.10 0.039 0.95 0.268
11 BARX2 rs11820646 A 0.489 0.509 1.09 (0.93, 1.28) 0.08 0.278 0.95 0.574
12 ATF7IP rs12422552 C 0.273 0.325 1.29 (1.08, 1.53) 0.09 0.004 1.06 0.128
12 PTHLH rs10771399 G 0.192 0.173 0.88 (0.71, 1.08) 0.11 0.221 0.86 0.729
12 NTN4 rs17356907 G 0.253 0.247 0.98 (0.82, 1.18) 0.09 0.839 0.91 0.604
14 PAX9/SLC25A21 rs2236007 A 0.297 0.255 0.83 (0.69, 0.98) 0.09 0.031 0.92 0.469
14 CCDC88C rs941764 G 0.126 0.140 1.13 (0.90, 1.42) 0.12 0.308 1.06 0.931
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Table 2 The rare allele frequencies of 51 single nucleotide polymorphisms (SNPs) in breast cancer patients and control
subjects and their association with risk of breast cancer, The Singapore Chinese Health Study, 1993 to 1998 (Continued)
16 TOX3 rs4784227 T 0.245 0.274 1.17 (0.97, 1.41) 0.09 0.098 1.23 0.574
16 TOX3 rs3112612 G 0.228 0.210 0.90 (0.74, 1.10) 0.10 0.300 1.13 0.066
16 CDYL2 rs13329835 G 0.053 0.054 1.02 (0.70, 1.46) 0.18 0.938 1.09 0.351
16 MIR1972-2/FTO rs17817449 C 0.140 0.118 0.83 (0.66, 1.06) 0.12 0.134 0.93 0.079
18 AQP4‡ rs527616 G 0.267 0.266 0.99 (0.83, 1.19) 0.09 0.951 0.98 0.805
18 CHST9 rs1436904 C 0.486 0.509 1.09 (0.93, 1.28) 0.08 0.287 0.96 0.225
19 C19orf61:KCNN4:LYPD5:ZNF283 rs3760982 A 0.136 0.148 1.10 (0.87, 1.38) 0.12 0.437 1.06 0.994
21 NRIP1 rs2823093 A 0.035 0.032 0.90 (0.57, 1.40) 0.23 0.631 0.92 0.994
†A pooled odds ratio (pOR) was not obtained for rs11242675 due to significant heterogeneity with other published studies; ‡a pOR with the Asian studies was
obtained due to heterogeneity with the results of European studies.*P value was derived from conditional logistic regression analysis. Chr, chromosome; RAF, risk
allele frequency; FDR, false discovery rate.
Table 3 The relation for genetic risk score and established conventional risk factors with risk of breast cancer, The
Singapore Chinese Health Study, 1993 to 1998
Variable Case
(n = 411),
n (%)
Control
(n = 1,212),
n (%)
OR (95% CI) P value Adjusted
OR (95% CI)ᶲ
P value Adjusted
OR (95% CI)‡
P value
Genetic risk score, quartiles (range), mean
First (32.4-43.6), 40.4 80 (19.5) 326 (26.9) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Second (43.6-47.1), 45.4 96 (23.4) 310 (25.6) 1.26 (0.90, 1.75) 0.178 1.25 (0.90, 1.75) 0.182 1.26 (0.90, 1.76) 0.174
Third (47.1-50.6), 48.9 109 (26.5) 296 (24.4) 1,47 (1.06, 2.04) 0.020 1.49 (1.07, 2.06) 0.017 1.47 (1.06, 2.04) 0.022
Fourth (50.6-65.8), 53.6 126 (30.7) 280 (23.1) 1.78 (1.29, 2.44) <0.001 1.74 (1.26, 2.40) 0.001 1.75 (1.27, 2.41) 0.001
P trend 1.21 (1.09, 1.33) <0.001 1.20 (1.09, 1.33) <0.001 1.20 (1.08, 1.33) <0.001
Age at first live birth, years
<20 56 (13.6) 212 (17.5) 1.00 (ref) 1.00 (ref) 1.00 (ref)
20-24 129 (31.4) 458 (37.8) 1.11 (0.77, 1.59) 0.571 1.04 (0.72, 1.50) 0.823 1.05 (0.73, 1.51) 0.804
25-29 or null 175 (42.6) 416 (34.3) 1.67 (1.16, 2.39) 0.005 1.51 (1.04, 2.18) 0.030 1.49 (1.03, 2.15) 0.036
≥30 51 (12.4) 126 (10.4) 1.62 (1.03, 2.55) 0.038 1.46 (0.92, 2.31) 0.111 1.49 (1.03, 2.29) 0.131
P trend 1.25 (1.09, 1.42) 0.001 1.20 (1.05, 1.38) 0.008 1.19 (1.04, 1.37) 0.011
Age at menarche, years
≥14 160 (38.9) 540 (44.6) 1.00 (ref) 1.00 (ref) 1.00 (ref)
12-13 180 (43.8) 484 (39.9) 1.29 (1.00, 1.66) 0.049 1.21 (0.93, 1.56) 0.151 1.23 (0.94, 1.60) 0.126
<12 71 (17.3) 188 (15.5) 1.34 (0.95, 1.89) 0.097 1.20 (0.84, 1.71) 0.312 1.19 (0.83, 1.71) 0.345
P trend 1.18 (1.00, 1.39) 0.048 1.12 (0.94, 1.32) 0.208 1.11 (0.94, 1.33) 0.220
Family history
No 400 (97.3) 1196 (98.7) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Yes 11 (2.7) 16 (1.3) 2.11 (0.97, 4.61) 0.061 2.06 (0.94, 4.52) 0.071 1.78 (0.79, 4.00) 0.162
Past breast biopsy, n (%)
No 401 (97.6) 1193 (98.4) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Yes 10 (2.4) 19 (1.6) 1.55 (0.69, 3.48) 0.288 1.36 (0.60, 3.08) 0.462 1.36 (0.58, 3.20) 0.475
Body mass index, kg/m2
<20 51 (12.4) 167 (13.8) 1.00 (ref) 1.00 (ref) 1.00 (ref)
20 to <24 216 (52.6) 659 (54.4) 1.09 (0.77, 1.54) 0.632 1.11 (0.78, 1.58) 0.562 1.16 (0.81, 1.66) 0.423
24 to <28 102 (24.8) 305 (25.2) 1.10 (0.75, 1.62) 0.610 1.12 (0.76, 1.64) 0.558 1.15 (0.78, 1.70) 0.488
28 or higher 42 (10.2) 81 (6.7) 1.74 (1.07, 2.85) 0.027 1.83 (1.12, 3.01) 0.016 1.99 (1.21, 3.29) 0.007
P trend 1.14 (0.99, 1.31) 0.067 1.15 (1.00, 1.33) 0.048 1.17 (1.02, 1.35) 0.031
ᶲAdjusted for education; ‡adjusted for education and all other factors in the table. OR, odds ratio; CI, confidence interval.
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Table 4 Reclassification of five-year absolute risk of breast
cancer based on a risk model containing Gail variables
with and without genetic risk scores (GRS) on 411 breast
cancer patients and 1,212 healthy women, The Singapore
Chinese Health Study, 1993 to 1998
Five-year
risk without
GRS (%)
Five-year risk with GRS (%)
<1.0 1.0 - <1.5 1.5 - <2.0 2.0 - <2.5 ≥2.5 Total
<1.0
Control 511 84 0 0 0 595
Case 109 46 0 0 0 155
1.0 - <1.5
Control 90 356 33 0 0 479
Case 36 123 39 0 0 198
1.5 - <2.0
Control 0 53 50 12 0 115
Case 0 13 19 12 0 44
2.0 - <2.5
Control 0 0 12 3 1 16
Case 0 0 4 2 3 9
>2.5
Control 0 0 0 2 5 7
Case 0 0 0 1 4 5
Total
Control 601 493 94 18 6 1,212
Case 145 182 62 15 7 411
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http://breast-cancer-research.com/content/16/3/R64effects in the former [68]. Our study also supports the find-
ing that the MAP3K SNP, rs889312, does not increase the
risk of breast cancer among the Chinese [31,38,56], con-
trary to that of European populations [7,33]. However,
unlike the other studies [7,8,31,33,37,38], statistical signifi-
cance was not observed here for another well-established
susceptibility loci containing FGFR2.
The OR of rs11242675 (FOXQ1) reported here was 1.15.
This is contradictory to the findings of many published
works, which have reported statistically significant pro-
tective effects, but the risk effect we found is supported by
the most recent BCAC study [46]. As a result, significant
heterogeneity was observed among the various studies
and a pOR was not applicable. Forkhead box Q1 (FOXQ1)
is a transcription factor found on the 6p25 locus. Overex-
pression of the protein has been shown to enhance
tumorigenicity and tumor growth through its angiogenic
and anti-apoptotic properties [69]. Its novel role in the
metastasis of breast cancer has also been suggested [70].
In view of a plausible biological function of FOXQ1 in
promoting cancer aggression, as well as marginal statis-
tical significance that was a likely consequence of small
sample size, rs11242675 was included in the GRS for risk
assessment.Another SNP that was also considered in the GRS
due to its marginally significant P value (P = 0.098) was
rs4784227. Rs4784227 is situated at 16q12.1 [71] and
has been predicted to interfere with the affinity of FOXA1,
an essential component of ESRα signaling [72], to its
binding site [73]. Its position in a regulatory region
that interacts with the TOX3 promoter enables it to
disrupt the expression of this gene, which in turn alters
chromatin structure and DNA-protein binding pat-
terns essential for cell survival [71]. An OR of 1.17 was
seen in our study. This effect size and direction were
similar to the findings of others thus a pOR was used
for GRS computation.
It was observed, in Figure 2, that the marginal im-
provement in model performance was not proportional
to the increase in additional SNPs used. Although the
discovery of additional SNPs do not drastically improve
the assessment of breast cancer risk, this is expected
since the first few new SNPs discovered would have been
associated with much larger effect sizes. Also, as the cost
of genotyping continues to decrease, we expect the use
of additional SNPs in risk assessment to be cost-effective
in the near future.
This study has several strengths. The study was nested
within a population-based prospective cohort that pro-
vides the use of questionnaire data collected before the
occurrence of breast cancer to reduce recall and reverse
causality bias. The inclusion of genetic variants in risk
assessment is advantageous as it is not subjected to
time-dependent errors in measurement, unlike environ-
mental exposures such as BMI or smoking. We have also
shown the strength of the association between GRS and
breast cancer risk; it remains virtually unchanged even
after all other established risk factors have been consid-
ered, highlighting the importance of genetics in this
aspect.
There are also several limitations in our study. The
small sample size of approximately 1,600 women has
made it difficult to attain statistical significance for most
of the SNPs that were identified in GWAS studies.
Nevertheless, the direction of the effects of most SNPs
was consistent with the published literature. As all the
subjects recruited were Chinese women, this could re-
strict the generalizability of our results. Studies will need
to be conducted in larger populations and among
women of other ethnicities to validate the effect of these
polymorphisms. We were not able to consider two fac-
tors in this study: 1) the presence of copy number varia-
tions (CNVs) and their potential effects on breast cancer
risk and 2) the various subtypes of the disease. Given the
proximity of some SNPs to CNV regions [74], and the
relation between CNVs and familial breast cancer [75],
an effect of CNVs on risk of disease is not unlikely.
However, modeling this poses difficulties and may not
Figure 2 Effect of increasing number of SNPs in breast cancer risk assessment. The rate of increase in model discriminatory power
(difference in log five-year absolute risk) between cases and controls diminishes as more SNPs are incorporated into the GRS. For instance, the
change in improvement of model performance is minimal when the number of SNPs used in the GRS increased from 16 to 51. GRS is obtained
by pooling the ORs of local and published studies. Y-axis is the density that reflects the frequency of subjects. (Black - controls, Red - cases). SNP,
single nucleotide polymorphism; GRS, genetic risk score; OR, odds ratio.
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http://breast-cancer-research.com/content/16/3/R64alter the results substantially [74]. Although further ana-
lysis by disease subtype would have been ideal, we were
restricted by the study’s limited sample size and power.
Finally, the breast cancer cases included in this study
from the cohort had a higher prevalence for positive
family history of breast cancer compared to cases that
were not included in this study, although this prevalence
was still generally low (2.7%).Conclusions
In summary, we have shown the extent to which 51 SNPs
may improve the current assessment of breast cancer risk.
Most of the SNPs identified in other Western and Asian
studies have presented similar effect sizes in our Singapore
Chinese population. Despite conferring minimal increase in
risk, individual genetic variants when considered cumula-
tively can result in considerable effects, leading to improved
Lee et al. Breast Cancer Research 2014, 16:R64 Page 11 of 13
http://breast-cancer-research.com/content/16/3/R64risk stratification. By including a genetic component for risk
assessment, more targeted measures of prevention and
screening can be implemented. For countries such as
Singapore where breast cancer incidence is relatively low
and mammography screening is not as well-received, cost-
efficiency and ethical issues can be more aptly addressed.
Additional file
Additional file 1: Table S1. The corresponding individual and pooled
ORs from published GWAS studies for 51 SNPs. This table presents the
individual and pooled ORs, as well as FDR-corrected P-het of each SNP
from published studies. The pooled ORs for each SNP were obtained
from published studies only.
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